{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=64&sponsor=AstraZeneca",
    "query": {
      "sponsor": "AstraZeneca",
      "page": 64
    },
    "page_size": 10
  },
  "pagination": {
    "page": 64,
    "page_size": 10,
    "total_count": 1904,
    "total_pages": 191,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=65&sponsor=AstraZeneca&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=63&sponsor=AstraZeneca&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T14:08:10.941Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01563978",
      "title": "Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2012-04",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 30,
      "location_summary": "Huntsville, Alabama • Huntington Beach, California • Santa Maria, California + 27 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01563978"
    },
    {
      "nct_id": "NCT03071874",
      "title": "Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meningioma"
      ],
      "interventions": [
        {
          "name": "AZD2014",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2017-10-17",
      "completion_date": "2024-07-25",
      "has_results": false,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071874"
    },
    {
      "nct_id": "NCT03703297",
      "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 730,
      "start_date": "2018-09-27",
      "completion_date": "2026-10-23",
      "has_results": true,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 34,
      "location_summary": "Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03703297"
    },
    {
      "nct_id": "NCT01645735",
      "title": "Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infections"
      ],
      "interventions": [
        {
          "name": "Ceftaroline fosamil",
          "type": "DRUG"
        },
        {
          "name": "Ceftriaxone plus vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2012-10",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-01",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01645735"
    },
    {
      "nct_id": "NCT01603069",
      "title": "A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "AZD3241 300 mg BID",
          "type": "DRUG"
        },
        {
          "name": "AZD3241 600 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2012-10",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-07-19",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Long Beach, California • New Haven, Connecticut + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01603069"
    },
    {
      "nct_id": "NCT00114686",
      "title": "Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar I Disorder",
        "Alcohol Dependence"
      ],
      "interventions": [
        {
          "name": "Quetiapine fumarate",
          "type": "DRUG"
        },
        {
          "name": "lithium",
          "type": "DRUG"
        },
        {
          "name": "divalproex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 350,
      "start_date": "2006-01",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 38,
      "location_summary": "Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00114686"
    },
    {
      "nct_id": "NCT00515866",
      "title": "Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "KU-0059436 (AZD2281)(PARP inhibitor)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2007-08",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2013-12-20",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 2,
      "location_summary": "New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515866"
    },
    {
      "nct_id": "NCT04277546",
      "title": "Open-label Extension Study of Brazikumab in Ulcerative Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Brazikumab Maintenance Dose",
          "type": "DRUG"
        },
        {
          "name": "Brazikumab Induction Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 57,
      "start_date": "2020-03-03",
      "completion_date": "2023-10-10",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 10,
      "location_summary": "Chula Vista, California • Lancaster, California • Colorado Springs, Colorado + 7 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04277546"
    },
    {
      "nct_id": "NCT00893841",
      "title": "Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Depression"
      ],
      "interventions": [
        {
          "name": "quetiapine (Seroquel) XR",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "pramipexole dihydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 96,
      "start_date": "2009-02",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-02-04",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Kirkland, Washington",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00893841"
    },
    {
      "nct_id": "NCT00313794",
      "title": "Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "CP-675,206",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2006-05",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2012-06-07",
      "last_synced_at": "2026-11-05T14:08:10.941Z",
      "location_count": 9,
      "location_summary": "Bessemer, Alabama • Birmingham, Alabama • San Francisco, California + 1 more",
      "locations": [
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00313794"
    }
  ]
}